Sign in

NCT06938139Active, not recruiting

Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy

Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy: A Multicentre Analysis

Source: ClinicalTrials.gov · Last updated 22 Apr 2025

Brief summary (registry, in English)

The Benchmark-MISGC study was a large-scale retrospective observational study launched by the China Gastric Cancer Surgical Union, aiming to establish the benchmarks of the short- and long-term outcomes for gastric cancer patients who underwent minimal invasive gastrectomy.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
90000 (estimated)
First submitted
28 Mar 2025
Start date
1 Mar 2025
Primary completion date
30 Apr 2025
Lead sponsor
Fujian Medical University
NCT number
NCT06938139

What you commit to

  • Study type: Observational
  • Planned participants: 90000
  • From 1 Mar 2025 to the primary completion date, 30 Apr 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Palliative resection;

Other illness

  • remnant gastric cancer;
  • concurrent/previous malignant disease;

Other

  • ASA class \> 3;
  • Distant metastasis;
  • Abodominal exploration.

Who the study is looking for

  • Patients with postoperative histologically confirmed gastric adenocarcinoma at stages T1-4a, N0/+, M0;
  • underwent robotic or laparoscopic gastrectomies with curative intent

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Fujian Medical University Union Hospital
Coordinator of this site? Confirm its status
FuzhouChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.